HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $7
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $1.5 to $7.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $1.5 to $7.